Home
Siv Lise Bedringaas's picture

Siv Lise Bedringaas

Head Engineer
  • E-mailSiv.Bedringaas@uib.no
  • Phone+47 55 97 30 59+47 454 95 691
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • 2017. Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. Journal of Proteomics. 32-41.
  • 2015. 4-alkylated silver-N-heterocyclic carbene (NHC) complexes with cytotoxic effects in leukemia cells. ChemMedChem. 1522-1527.
  • 2010. Hypoxia increases HIF-1 alpha expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. European Cytokine Network. 154-164.
  • 2006. Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML). Current Pharmaceutical Biotechnology. 159-170.
Thesis at a second degree level
  • 1992. Tranfeksjon av den humane thyrocyt cellelinjen SGHTL-34 med oncogener og optimalisering av tranfeksjonsbetingelser.
Abstract
  • 2010. OXYGEN LEVELS INFLUENCE THE CYTOKINE RELEASE PROFILE OF AML CELLS. Experimental Hematology. S119-S119.
  • 2008. FLT3 internal tandem duplication involving its libiquitin dependent endocytosis motif suspend modulation by HDM2 and are associated with inferior survival in AML. Haematologica. 10-10.
  • 2007. Flt3 mutations in proximity to an ubiquitin dependent endocytosis motif suspend its Hdm2 modulation. Blood. 148B-148B.
  • 2007. Anti-tumor activity of immunoproteasome selective inhibitors. Blood. 477A-478A.
Poster
  • 2019. Synthesis and investigation of Ag-NHC complexes with cytotoxic properties towards cell lines modelling acute myeloid leukemia .
  • 2007. Flt3 Mutations in Proximity to an Ubiquitin Dependent Endocytosis Motif Suspend Its Hdm2 Modulation.
  • 2007. Anti-Tumor Activity of Immunoproteasome Selective Inhibitors.
Academic literature review
  • 2006. Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML). 159-170.

More information in national current research information system (CRIStin)